Research Analysts Set Expectations for IQVIA Q4 Earnings

IQVIA Holdings Inc. (NYSE:IQV) – Research analysts at Zacks Research lifted their Q4 2025 EPS estimates for shares of IQVIA in a research note issued on Monday, November 17th. Zacks Research analyst Team now expects that the medical research company will post earnings of $3.07 per share for the quarter, up from their prior estimate of $3.05. The consensus estimate for IQVIA’s current full-year earnings is $10.84 per share.

Other research analysts also recently issued reports about the company. Truist Financial restated a “buy” rating and issued a $265.00 price target (up from $235.00) on shares of IQVIA in a research note on Wednesday, October 29th. Redburn Partners set a $214.00 target price on IQVIA in a research report on Wednesday, September 3rd. JPMorgan Chase & Co. raised their price target on IQVIA from $177.00 to $255.00 and gave the company an “overweight” rating in a report on Wednesday, October 29th. HSBC raised IQVIA from a “hold” rating to a “buy” rating and upped their price objective for the stock from $195.00 to $235.00 in a report on Thursday, October 9th. Finally, Citigroup raised their target price on shares of IQVIA from $200.00 to $230.00 and gave the company a “neutral” rating in a report on Wednesday, October 29th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $240.61.

IQVIA Stock Performance

NYSE:IQV opened at $217.60 on Wednesday. The stock has a 50-day moving average price of $203.84 and a 200 day moving average price of $179.79. The stock has a market capitalization of $37.06 billion, a P/E ratio of 29.85, a P/E/G ratio of 2.43 and a beta of 1.34. IQVIA has a 12-month low of $134.65 and a 12-month high of $228.12. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business had revenue of $4.10 billion during the quarter, compared to analyst estimates of $4.07 billion. During the same quarter in the prior year, the business posted $2.84 EPS. IQVIA’s revenue for the quarter was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS.

Insider Activity

In related news, insider Eric Sherbet sold 4,000 shares of IQVIA stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the transaction, the insider directly owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. The trade was a 12.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Physician Wealth Advisors Inc. boosted its holdings in IQVIA by 1,340.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 134 shares during the period. Clal Insurance Enterprises Holdings Ltd boosted its stake in shares of IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 131 shares during the period. Westside Investment Management Inc. grew its holdings in shares of IQVIA by 219.6% in the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after purchasing an additional 101 shares during the last quarter. Measured Wealth Private Client Group LLC purchased a new position in IQVIA in the 3rd quarter worth about $30,000. Finally, AllSquare Wealth Management LLC bought a new stake in IQVIA during the 1st quarter valued at about $33,000. Institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.